Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HVP01: Hepatitis B Vaccine Mechanism
NCT03083158Phase 4Completed
- Sponsor
- University of British Columbia
- Start
- Mar 2017
- Primary completion
- Feb 2018
- Modality
- Split/Subunit Vaccines, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 4, open-label trial of Hepatitis B vaccine in hepatitis B (HBV) (2 arms), sponsored by University of British Columbia. Primary endpoint: Antibody response to the first dose of hepatitis B vaccine at 28 days. Started Mar 2017; status: completed.
02
Drugs
Hepatitis B vaccine
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT03083158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03083158.